Third biannual report of the Cochrane Haematological Malignancies Group.
Kober
Thilo
T
Cochrane Haematological Malignancies Group, Cologne, Germany. thilo.kober@medizin.uni-koeln.de
Skoetz
Nicole
N
Trelle
Sven
S
Bohlius
Julia
J
Engert
Andreas
A
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation; D002051:Burkitt Lymphoma / Q000628:therapy; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D004334:Drug Administration Schedule; D019337:Hematologic Neoplasms / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000628:therapy; D008224:Lymphoma, Follicular / Q000628:therapy; D016403:Lymphoma, Large B-Cell, Diffuse / Q000628:therapy; D020522:Lymphoma, Mantle-Cell / Q000628:therapy; D015337:Multicenter Studies as Topic; D009101:Multiple Myeloma / Q000628:therapy; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000628:therapy; D011446:Prospective Studies; D016032:Randomized Controlled Trials as Topic; D016019:Survival Analysis; D016896:Treatment Outcome